NDA 021441 · Haleon US Holdings
Advil Allergy Sinus
Chlorpheniramine Maleate, Ibuprofen, Pseudoephedrine Hydrochloride · Oral · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 20, 2026Latest source record: Nov 23, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Dec 19, 2002
Approved uses
1
Original approval plus efficacy supplements
Registered trials
53
11 Phase 3, 4 recruiting
FAERS reports
237
31 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 23, 2026.
Uses temporarily relieves these symptoms associated with hay fever or other upper respiratory allergies, and the common cold: runny nose itchy, watery eyes itching of the nose or throat sneezing nasal congestion sinus pressure headache minor aches and pains fever
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ADVIL ALLERGY SINUS · CHLORPHENIRAMINE MALEATE 2MG; IBUPROFEN 200MG; PSEUDOEPHEDRINE HYDROCHLORIDE 30MG · TABLET, ORAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Chlorpheniramine" as an intervention, any sponsor and status, largest first.
- Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.Pivotal-lookingRecruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT04688736 · 6,642 participants (planned) · Start Jan 1, 2021 · Primary completion Dec 31, 2026
Drug: Placebo; Chlorpheniramine · For: Allergic Transfusion Reaction
Sites: Hefei, China; Zhoukou, China; Tai’an, China · 4 sites in all
- Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)Pivotal-lookingCompleted
Organon and CoIndustry
NCT03879772 · 679 participants · Start Mar 12, 1996 · Primary completion Jul 1, 1996
Drug: Mometasone furoate nasal spray; Beclomethasone dipropionate nasal spray and 2 more · For: Rhinitis, Allergic, Seasonal
- Fixed-dose Combination of 1000 mg Dipyrone Monohydrate + 60 mg Caffeine + 4 mg Chlorpheniramine Maleate in Improving Symptoms of the Common Cold and Flu in AdultsPivotal-lookingRecruiting
Brainfarma Industria Química e Farmacêutica S/AIndustry
NCT07626437 · 620 participants (planned) · Start May 8, 2026 · Primary completion Jun 28, 2027
Drug: dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg; dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg and 1 more · For: Common Cold/Flu; Nasal Congestion; Nasal Obstruction
Sites: Belo Horizonte, Brazil; Vespasiano, Brazil; Belém, Brazil · 15 sites in all
- Effectiveness Study of Integrative Treatment for Pediatric PneumoniaPivotal-lookingCompleted
Liaoning University of Traditional Chinese MedicineAcademic, hospital or other
NCT02069665 · 451 participants · Start Dec 2011 · Primary completion Jul 2013
Drug: Xiyanping injection; Ribavirin Injection and 6 more · For: Pneumonia
Sites: Beijing, China; Guangzhou, China; Dalian, China · 6 sites in all
- Methods of T Cell Depletion Trial (MoTD)Pivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04888741 · 400 participants (planned) · Start Feb 22, 2021 · Primary completion Aug 23, 2027
Drug: Thymoglobulin; Cyclophosphamide and 3 more · For: Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelomonocytic Leukemia and 6 more
Sites: Cardiff, United Kingdom; Birmingham, United Kingdom; Bristol, United Kingdom · 17 sites in all
- NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)Pivotal-lookingCompleted
Cancer Trials IrelandResearch network
NCT01726452 · 377 participants · Start Jan 24, 2013 · Primary completion Aug 4, 2022
Drug: Epirubicin; Cisplatin / Oxaliplatin and 7 more · For: Adenocarcinoma of the Oesophagus; Adenocarcinoma of the Oesophago-gastric Junction; Oesophageal Tumours and 2 more
Sites: Blegdamsvej 9, Denmark; Lille, France; Cork, Ireland · 29 sites in all
- Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common ColdPivotal-lookingStatus unknown
Brainfarma Industria Química e Farmacêutica S/AIndustry
NCT02735070 · 366 participants (planned) · Start Sep 2016 · Primary completion Mar 2017
Drug: Resfenol; Coristina d · For: Cold
- Effect of the Antihistamine Injection to Prevent Paradoxical Reaction During Sedative EndoscopyStatus unknown
Seoul National University HospitalAcademic, hospital or other
NCT03940391 · 220 participants (planned) · Start May 1, 2019 · Primary completion Apr 14, 2020
Drug: Chlorpheniramine and midazolam; Midazolam · For: Endoscopy
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective79
- product use in unapproved indication30
- drug effective for unapproved indication23
- drug effect incomplete13
- dizziness10
- somnolence9
- headache8
- insomnia8
- therapeutic response unexpected8
- nausea7
- feeling abnormal6
- drug ineffective for unapproved indication5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 4 |
| 2011 | 23 |
| 2012 | 9 |
| 2013 | 13 |
| 2014 | 16 |
| 2015 | 28 |
| 2016 | 16 |
| 2017 | 6 |
| 2018 | 14 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 33 |
| 2022 | 8 |
| 2023 | 10 |
| 2024 | 11 |
| 2025 | 13 |
| 2026 | 8 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.
Fornaro M, Caiazza C, Solini N, et al. · Mol Psychiatry 2023 · Systematic Review, Network Meta-Analysis
- Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants.
Schifano F, Chiappini S, Miuli A, et al. · Front Psychiatry 2021 · Systematic Review
- Over-the-counter Psychosis: A Systematic Review of the Misuse of Antihistamines, Cough Medicines, and Decongestants and the Risk of Developing Psychosis.
Mosca A, Chiappini S, Mancusi G, et al. · Curr Neuropharmacol 2025 · Systematic Review
- Effect of arginine-fluoride varnish on preventing enamel erosion by paediatric liquid medicaments.
Yip K, Abdalla MM, Bijle MN, et al. · BMC Oral Health 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- WITHDRAWN: Antihistamines versus aspirin for itching in late pregnancy.
Young G, Jewell D · Cochrane Database Syst Rev 2010 · Systematic Review
- Factors associated with anticholinergic burden among older patients in long-term care hospitals in Korea.
Choi JY, Kim H, Jung YI, et al. · Korean J Intern Med 2022 · Randomized Controlled Trial, Pragmatic Clinical Trial
Sponsor: Haleon US Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.